ANTIPSYCHOTICS - ARIPIPRAZOLE

This tender focuses on the procurement of a specific pharmaceutical product: Aripiprazole, which is an antipsychotic medication. The contracting authority is seeking to acquire this drug, likely for use in healthcare facilities or for distribution to patients requiring treatment for conditions such as schizophrenia, bipolar disorder, or major depressive disorder. The tender specifies the active pharmaceutical ingredient, indicating a need for a particular generic or branded version of Aripiprazole. The procurement process will involve defining the required dosage forms (e.g., tablets, oral solution, injectable), strengths, quantities, and packaging specifications. Bidders are expected to be licensed pharmaceutical suppliers capable of providing high-quality, regulatory-compliant medications. The objective is to ensure the availability of Aripiprazole to meet patient needs within the healthcare system. This targeted procurement highlights the demand for specific treatments and the importance of a reliable pharmaceutical supply chain for essential medications.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 41,102.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.